about
Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directionsO-GlcNAcylation: a bridge between glucose and cell differentiationChildhood obesity, bone development, and cardiometabolic risk factorsThe alliance of mesenchymal stem cells, bone, and diabetesAdvanced glycation end products play adverse proinflammatory activities in osteoporosisAdvanced glycation end products and diabetic complicationsAptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Focal therapeutic irradiation induces an early transient increase in bone glycation.Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent mannerArthroplasty in veterans: analysis of cartilage, bone, serum, and synovial fluid reveals differences and similarities in osteoarthritis with and without comorbid diabetes.Bone fragility in type 2 diabetes mellitus.Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.Influence of high glucose and advanced glycation end-products (ages) levels in human osteoblast-like cells gene expression.Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.Determinants of bone strength and quality in diabetes mellitus in humans.Diabetes and Its Effect on Bone and Fracture Healing.Advanced Glycation End-products and Bone FracturesBone quality in diabetes.Bone metabolism and fracture risk in type 2 diabetes mellitus.Bone mechanical properties and changes with osteoporosis.RAGE and its ligands in bone metabolism.A review of rodent models of type 2 diabetic skeletal fragility.Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosisReview: The diabetic bone: a cellular and molecular perspective.Type 2 diabetes and bone.Antidiabetic therapy effects on bone metabolism and fracture risk.Impact of diabetes and its treatments on skeletal diseases.Diabetes, collagen, and bone quality.Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease.Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk?Bone cells and bone turnover in diabetes mellitus.The impact of type 2 diabetes on bone metabolism.Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients.Effects of dietary bread crust Maillard reaction products on calcium and bone metabolism in rats.Dietary Advanced Glycation End Products have Sex-and Age Dependent Effects on Vertebral Bone Microstructure and Mechanical Function in Mice.Fracture risk assessment in postmenopausal women with diabetes: comparison between DeFRA and FRAX tools.Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.Bone Formation is Affected by Matrix Advanced Glycation End Products (AGEs) In Vivo.Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
P2860
Q26750574-64365CD2-1A9E-4EAF-B6CE-5F970D9BFF0AQ26765379-01E054F1-1296-468D-9BEB-4BBD1F039EE5Q26853091-65FF11DD-8EAB-4F64-AF10-EA77F03F4FC6Q27012497-0A0E14F9-93BC-456E-ADA6-8F4DA64DBE5FQ27024641-0934194A-47FC-4F0F-A5B3-7C2168A4DB11Q27687501-78EF1330-927E-4152-B2DC-EA7CC55407B6Q33901933-98ED1871-BFCC-4CB4-9408-9CA06C3AC164Q35245623-4FAB2618-4296-4D6B-A75E-D32F21EAB4F1Q35795868-3595981D-62A4-4842-9A14-6F469A74A1B4Q35804646-528204DE-1104-42A9-99E5-B09062F6D3E5Q35825346-26B0BF20-A021-4EBE-876E-0BAB4E3F160BQ35963018-CA3B5F5E-A312-422F-92C2-994791C3CA59Q36119266-DF19245D-B6BD-4B40-9F41-05071C1E1EE2Q36372679-DA0B0826-24BC-4357-8D85-DEDD2387C5CDQ36373016-48B46635-B713-44BD-8A27-E7E35C2EDFC5Q36407732-2EC93C84-B37F-4136-96B6-931FE9581B55Q36868071-9A359FF6-135E-49A2-8E5B-E3A4F75AFBF3Q36927957-6C24FCD5-1B83-47BB-A369-A52882A0F077Q37056305-3AA93D1B-9709-42B9-A91E-F7435F1FA53BQ37113961-9200344E-183D-42F7-93CF-0B99B1763347Q37274344-EDA5FAA6-F6D9-49A4-871F-14BCA106BC09Q37650212-44B6FBE1-DD0C-429A-92DE-0D40CDBC6EC5Q37673039-9C2A31F6-747A-441A-92CF-82163C49B2DEQ37858842-358897DA-A3C4-4832-986E-5ACA7C65A432Q38048186-2A65C9E1-6C9B-4897-A212-5938B960693DQ38078009-C0F5126B-03F7-467E-9B9A-8BFB4B509D58Q38078839-AD45D2AD-9C43-458E-9C8F-73A9585664C7Q38195566-60119B9C-C842-4742-B2DA-010537DB8C5DQ38384409-4F3358AC-47C2-43FF-9F50-BBFA37EC25BFQ38776127-0633A2D0-7D86-4432-B878-B98CED25BF11Q38945656-62EA9102-1913-48A8-BD39-453EDBFDBCCAQ41294180-0DF90CDB-AB09-4FDC-8D94-695752B29B33Q42660007-B9211437-F583-46AA-B892-F6708DDB2136Q44414030-F0816838-AA72-407B-BF17-465918FF5369Q46042155-E54DCF81-2721-48E1-A1E5-4A50CDD9C067Q47327491-A09FB522-5090-4083-9D08-A74CF7F3E309Q49667245-C6D3F109-E8C1-4795-A644-A4C752C17D6EQ50223052-5CBCE616-7C68-440A-8068-459BBA16FBBDQ51311945-0D523B37-0811-4E09-8932-8EA1B99D8874Q58577346-C23A2794-EA4F-4AD4-867B-554F9D8CCB46
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pentosidine effects on human osteoblasts in vitro.
@en
Pentosidine effects on human osteoblasts in vitro.
@nl
type
label
Pentosidine effects on human osteoblasts in vitro.
@en
Pentosidine effects on human osteoblasts in vitro.
@nl
prefLabel
Pentosidine effects on human osteoblasts in vitro.
@en
Pentosidine effects on human osteoblasts in vitro.
@nl
P50
P356
P1476
Pentosidine effects on human osteoblasts in vitro
@en
P2093
Alberto Federici
Daniela Storace
P304
P356
10.1196/ANNALS.1433.044
P407
P577
2008-04-01T00:00:00Z